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Abstract
Background: Little is known about the impact of severity of hypertension on the association of
genes with high blood pressure, which may cause the inconsistently reported associations of
peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) gene with blood pressure.
Methods: A cardiovascular epidemiology survey and genotyping were performed in a population-
based sample of 1642 apparently healthy residents (648 men and 994 women aged 35–91 years).
Results: After adjusting for age, sex, body mass index, and antihypertensive medication, G482S and
+2962A/G polymorphisms were significantly associated with systolic blood pressures in
hypertension patients with medication use (p = 0.023 and 0.022 for G482S and +2962A/G
respectively) but not in all participants, normotensives, and patients with no medication use.
Multivariable logistic models showed that the two polymorphisms were significantly associated with
severe hypertension (SBP ≥ 160 mm Hg or DBP ≥ 100 mm Hg regardless of medication use), with
an OR of 0.6(95% confidence interval [CI]: 0.4–0.98) for S482S vs. G482G and an OR of 1.9(95%
CI: 1.2–3.0) for +2962G/G vs. +2962A/A, but not with regular hypertension (SBP ≥ 140 mm Hg or
DBP ≥ 90 mm Hg or current use of antihypertensive medications), with an OR of 0.9(95% CI: 0.7–
1.2) for S482S vs. G482G and an OR of 0.9(95% CI: 0.7–1.4) for +2962G/G vs. +2962A/A.
Haplotype combination analyses showed a significant synthetic effect (OR of severe hypertension
for persons with G482X and +2962G/G = 2.6, 95%CI: 1.5–4.4, with reference to persons with
S482S and +2962A/X).
Conclusion: In this study, we found that G482S and +2962A/G polymorphisms of PGC-1α gene
were only significantly associated with severe hypertension defined by occasional clinic blood
pressure measurements. This finding suggested severe hypertension rather than regular
hypertension should be used as the outcome in studies on association of genes with blood pressure
or hypertension, in order to have a better power.
Published: 31 October 2007
BMC Cardiovascular Disorders 2007, 7:33 doi:10.1186/1471-2261-7-33
Received: 23 May 2007
Accepted: 31 October 2007
This article is available from: http://www.biomedcentral.com/1471-2261/7/33
© 2007 Xie et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cardiovascular Disorders 2007, 7:33 http://www.biomedcentral.com/1471-2261/7/33
Page 2 of 7
(page number not for citation purposes)
Background
Hypertension is the most common risk factor for cardio-
vascular and cerebrovascular diseases and affected over 1
billion individuals worldwide[1,2]. Although some risk
factors of hypertension such as high sodium intake, inac-
tivity, obesity, familial history, etc. have been identified,
genetic factors of hypertension at gene level remain
unclear. This is possibly partly due to so called "minor
effect" of the genes[3]. Also, it is possibly due to dilution
effect from environment factors because of using a lower
cut off of blood pressure to define hypertension cases.
However, few studies have examined this hypothesis.
Peroxisome proliferator-activated receptors gamma coac-
tivator 1 alpha (PGC-1α, Gene ID, No. 10891) is a coacti-
vator of several nuclear receptors including peroxisome
proliferator-activated receptors α and γ, thyroid hormone
receptor, mineral corticoid receptor and estrogen recep-
tors, and was considered involving in blood pressure reg-
ulation [4,5]. Recently, several western population studies
have studied the associations of Gly482Ser (G482S) and
+2962A/G single nucleotide polymorphisms (SNP) of
PGC-1α gene with blood pressure [6-10]. However, the
associations were inconsistent in different studies, even in
the same ethnic populations. Moreover, the association
has not been studied in Asian populations.
The aim of this study was to investigate whether the
G482S and +2962A/G polymorphisms in the PGC-1α
gene were associated with blood pressure and the impact
of severity of hypertension on the association of PGC-1α
Gene with blood pressure and risk of hypertension in a
middle-aged and elderly population in China.
Methods
Study population
We drew our study participants from 10 villages in a
northern Chinese population in 2004. To be recruited in
the study, the participant must be a registered resident and
living in the village in the year of survey. Among 8217 reg-
istered residents, 2835 met the inclusion criteria of ≥35
years of age, and out of them 2409 were living in the vil-
lage at the year of survey and thus invited. Among the
invited, 1998 accepted to participate and gave their
informed consent; and 1701 had their genotypic informa-
tion. We excluded 59 patients with myocardial infarction
and stroke from analyzed population. We also excluded 5
participants with missing data of blood pressure. Finally
1642 participants were included in our analyses. The
study was approved by the Ethical Committee of Fuwai
Hospital according to the Declaration of Helsinki. The
written informed consent was obtained from all partici-
pants.
Blood Pressure Measurement
Three BP measurements were obtained from each partici-
pant using a standard mercury sphygmomanometer by
trained and certified observers, according to a standard
protocol described in detail elsewhere[11,12]. The average
of the 3 blood pressure readings were used to define
hypertension and for analysis in the present paper. Cur-
rent use of antihypertensive medication was determined
by a "yes" or "no" answer to the Chinese equivalent of the
question, "Have you taken antihypertensive drugs in the
past 2 weeks?"
To explore the impact of severity of hypertension on the
association between the gene and hypertension (or blood
pressure), we used different cut offs to define hyperten-
sion. First, we defined hypertension using the current
widely accepted criteria [2] as SBP ≥ 140mmHg or DBP ≥
90 mmHg or current use of antihypertensive medications.
We referred it as "regular hypertension" in this paper.
Then, we also defined hypertension as SBP ≥ 160mmHg
or DBP ≥ 100mmHg regardless of using antihypertensive
medication. We referred it as "severe hypertension" in this
paper.
Body Mass Index (BMI)
Body height was measured to the nearest centimeter (cm)
using a standard right-angle device. Body weight was
measured to the nearest kilogram by using a spring bal-
ance. Each participant was measured in typical indoor
clothing, without shoes, and in a standing position. BMI
was defined as weight/height2 (kg/m2).
Genotyping
We genotyped the G482S (refSNP ID: rs8192678) and
+2962A/G (refSNP ID: rs6821591) polymorphisms in the
PGC-1α gene using DNA MassARRAY Technology[13,14].
Briefly, a fragment (approximately 100bp) containing the
SNP site was amplified by PCR first. All PCR reactions
were performed on an ABgene (#TF-0384), 384 well PCR
plate. The sample plate and a 384 SpectroCHIP were
placed on the deck of the SpectroPOINT robot. The robot
transferred a few nanolitres of solution from the sample
plate onto the chip and calibrant was transferred from res-
ervoir onto calibrant patches of 384 SpectroCHIP. The
chip was read in the Bruker Autoflex Mass Spectrometer
system.
Statistical Analysis
SHEsis software[15] was used for Hardy-Weinberg equi-
librium test, haplotype construction, and linkage analy-
ses. Chi-square test (χ2) and odds ratio (OR) test were
used for dichotomous variables. Logistic regression and
ANOVA were used for adjustment for multiple covariates
including sex, age, body mass index (BMI), and antihyper-
tensive treatment, using Version 9.0 of SAS system forBMC Cardiovascular Disorders 2007, 7:33 http://www.biomedcentral.com/1471-2261/7/33
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Windows. A p-value less than 0.05 was considered statis-
tically significant. Statistical power was calculated accord-
ing to the following formula.
In this formula, n is the total number of participants, p is
total prevalence of hypertension, p1 and p2 are prevalence
of hypertension in two compared genotypes groups, α =
0.05 was permitted as possibility of type I errors (Z1-α/2 =
1.96). Then Z1-β is calculated and statistical power is esti-
mated.
The difference of ORs was tested using Z-test according to
the following formula.
Results
General characteristics of participants
Table 1 showed general characteristics of the participants.
Briefly, 648 men and 994 women participated in the
study. The age varied from 35 to 91 years and was 53 years
old on average. The prevalence was 48% for regular hyper-
tension and 16% for severe hypertension. The severe
hypertension accounted for 33.7% of the regular hyper-
tension. 56.6% of regular hypertension and 59.3% of
severe hypertension used antihypertensive medications in
the past 2 weeks (Table 1).
Distribution of G482S and +2962A/G genotypes
The frequencies of wild-type (G482G), heterozygous
(G482S), and variant genotypes (S482S) were 0.311,
0.496, and 0.192. The frequencies of wild-type (+2962A/
A), heterozygous (+2962A/G), and variant genotypes
(+2962G/G) were 0.512, 0.390, and 0.098 respectively.
The distributions were consistent with Hardy-Weinberg
equilibrium (HW-E) for G482S polymorphisms (p =
0.780) but not for +2962A/G (p = 0.018). In addition, the
wild-type and variant allele frequencies for G482S poly-
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Table 1: Characteristics of study population
Variables Values
No. of participants 1642
% of men (No.) 39.46%(648)
Age, years 52.8(10.2)
BMI, kg/m2 24.2(3.7)
SBP, mmHg 134.9(21.8)
DBP, mmHg 82.9(10.9)
Regular hypertension* 48.4%(795)
Severe hypertension** 16.3%(268)
Antihypertensive medication use,% 27.41%(450)
Antihypertensive medication use among regular hypertension,% 56.6%(450)
Antihypertensive medication use among severe hypertension,% 59.3%(159)
Gly482Ser genotypes
S482S 19.24%(316)
G482S 49.63%(815)
G482G 31.12%(511)
+2962A/G genotypes
+2962A/A 51.16%(840)
+2962A/G 39.04%(641)
+2962G/G 9.81%(161)
Haplotype combination
S482S||+2962A/A 19.0% (312)
S482S||+2962A/G 0.2% (4)
S482S||+2962G/G 0(0)
G482S||+2962A/A 23.9% (392)
G482S||+2962A/G 25.6% (421)
G482G||+2962A/A 8.3% (136)
G482G||+2962A/G 13.2% (216)
G482S||+2962G/G 0.1% (2)
G482G||+2962G/G 9.7% (159)
Data are presented as mean(SD) or %(n);
* Regular hypertension: SBP  140 mm Hg or DBP  90mm Hg or current use of antihypertensive medications;
** Severe hypertension: SBP  160 mm Hg or DBP  100mm Hg, regardless of medication use.BMC Cardiovascular Disorders 2007, 7:33 http://www.biomedcentral.com/1471-2261/7/33
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morphism were 0.559 and 0.441. Respective frequencies
for the +2962A/G were 0.707 and 0.293. Estimated hap-
lotype frequencies were 0.269, 0.291, 0.438, and 0.002
for the double-wild-type allele (482G/+2962A), the allele
with the variant nucleotide at +2962(482G/+2962G), the
allele with the variant nucleotide at G482S (482S/
+2962A), double-variant allele (482S/+2962G), respec-
tively. There were no significant differences between men
and women in genotype, allele, or estimated haplotype
frequencies.
Linkage analyses of G482S and +2962A/G
There was significant linkage disequilibrium between the
+2962A/G and G482S polymorphism (D' = 0.981, p <
0.001). The distribution of the +2962A/G polymorphism
was significantly associated with the distribution of the
G482S polymorphism. The percentage of carriers of
+2962 G/G were 0%,0.3%, and 31.1% among carriers of
S482S, G482S, and G482G genotypes, and the corre-
sponding percents of carriers of the +2962A/A genotype
were 98.7%,48.1%, and 26.6% (p < 0.0001).
Association of G482S and +2962A/G to blood pressure
We compared blood pressure among genotype groups.
After adjustment for age, sex, body mass index, and cur-
rent use of antihypertensive medication, SBP and DBP
were not significantly associated with G482S genotypes (p
= 0.266) or +2962A/G genotypes (p = 0.103) (Table 2).
Sex-specific analyses showed similar results (data not
shown in table). In order to exclude the confounding
effect of antihypertensive medication, we analyzed the
associations in three subgroups: 1) normal blood pressure
free from current use of antihypertensive medications; 2)
hypertension free from current use of hypertensive medi-
cations; 3) current use of antihypertensive medications.
We found a significant association of SBP to G482S geno-
types (p = 0.023) and +2962A/G genotypes (p = 0.020) in
subgroup 3 but not in subgroup 1 or 2 (Table 3).
Association of G482S and +2962A/G to hypertension
The prevalence of regular hypertension varied but did not
differ among genotype groups for both G482S and
+2962A/G. Adjustment for sex, age, body mass index did
not change the results (Table 4).
The prevalence of severe hypertension differed at border-
line significance among genotype groups for G482S and
significantly for +2962A/G. After adjustment for age, sex,
body mass index, and current use of antihypertensive
medications, risk of severe hypertension was significantly
lower for S482S in comparison with that for G482G (OR
= 0.6; 95% confidence interval [CI]: 0.4–0.98) and signif-
icantly higher for +2962G/G than that for +2962A/A (OR
= 1.9, 95% CI: 1.2–3.0). Sex-specific OR for +2962G/G vs.
+2962A/A were 2.2(95%CI: 1.03–4.5) for men and
1.9(95%CI: 1.1–3.2) for women. However, sex-specific
OR for G482S polymorphisms was no longer significant
(OR = 0.6, 95%CI: 0.4–1.1 for men, OR = 0.7, 95%CI:
0.4–1.1 for women for S482S vs. G482G).
Association of G482S and +2962A/G haplotype 
combination to hypertension
According to results from Table 4, we grouped all possible
combinations of haplotype into 4 groups as shown in
Table 5. The results clearly showed a synthetic effect of
G482S and +2962A/G in developing severe hypertension
but not for regular hypertension.
Post hoc analysis of power
To understand whether our study has enough statistical
power to conclude, we did analysis of power using the
number of participants, prevalence of hypertension, and
permitted possible type I error. The results showed that we
had a power of 90% in analysis for the association of
G482S genotype to the risk of severe hypertension, but it
was only 46% for regular hypertension. For +2962A/G, we
had 99% power for severe hypertension and only 4% for
regular hypertension. For haplotype combination, we had
Table 2: Muti-variable-adjusted means of blood pressure (mm Hg) and standard errors by Gly482Ser and +2962A/G polymorphisms in 
1642 participants
Genotypes N SBP(mm Hg) DBP(mm Hg)
G482S genotypes
G482G 511 139.2(0.9) 85.2(0.5)
G482S 815 139.4(0.7) 84.7(0.4)
S482S 316 137.4(1.1) 84.6(0.6)
p values 0.266 0.630
+2962A/G genotypes
+2962A/A 840 138.8(0.7) 84.7(0.4)
+2962A/G 641 138.6(0.8) 84.9(0.4)
+2962G/G 161 141.3(1.5) 85.4(0.8)
p values 0.103 0.695
Note: values were adjusted for age, sex, BMI, and current use of antihypertensive medications.BMC Cardiovascular Disorders 2007, 7:33 http://www.biomedcentral.com/1471-2261/7/33
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99% power for severe hypertension and only 14% for reg-
ular hypertension.
Discussion
Our study has a number of strengths. First, its study pop-
ulation was community-based. Secondly, International
standardized methodology and quality control proce-
dures were used, as part of the China Multicenter Collab-
orative Study of Cardiovascular Epidemiology[16].
Thirdly, genotyping was conducted in the Beijing Genom-
ics Institute Life Tech Co. Ltd. which was one of genotyp-
ing centres for the International HapMap Consortium
[17]. Theses gave us a better opportunity to detect the true
association of our interested genotypes to hypertension.
In our study, G482S and +2962A/G polymorphisms and
their haplotypes were found significantly associated with
risk of sever hypertension but not with that of regular
hypertension. These findings were confirmed by our find-
ings that these two SNPs were significantly associated with
blood pressure in patients using antihypertensive medica-
tions but not in all participants, normotensives or patients
with no medication, and were independent of age, sex,
body mass index, and antihypertension medication use.
These findings are well in accordance with the current
knowledge of hypertension that the disease is caused by
not only genetic factors but also environment factors[3].
It is those who exposed to both genetic and environment
factors develops severe hypertension and thus had a better
power to detect the effect of gene, while those who
exposed to only environment factors or genetic factors
Table 4: Prevalence and odds ratios (ORs) of regular and severe hypertension by PGC-1α polymorphisms in 1642 participants
Regular hypertension* Severe hypertension**
Genotypes Total No. Cases Prevalence,% OR1(95%CI) Cases Prevalence,% OR2(95%CI) p values for OR1 vs. OR2
G482S genotypes
G482G 511 261 51.1% 1.0 91 17.8% 1.0
G482S 815 387 47.5% 0.9(0.7–1.1) 139 17.1% 1.0(0.8–1.4) 0.503
S482S 316 147 46.5% 0.9(0.7–1.2) 38 12.0% 0.6(0.4–0.98) 0.177
p values 0.335 0.667 0.067 0.064
+2962A/G genotypes
+2962A/A 840 411 48.9% 1.0 128 15.2% 1.0
+2962A/G 641 305 47.6% 0.9(0.7–1.1) 102 15.9% 1.1(0.8–1.4) 0.407
+2962G/G 161 79 49.1% 0.9(0.7–1.4) 38 23.6% 1.9(1.2–3.0) 0.015
p values 0.863 0.623 0.030 0.011
* Regular hypertension: SBP  140 mm Hg or DBP  90mm Hg or current use of antihypertensive medications;
** Severe hypertension: SBP  160 mm Hg or DBP  100mm Hg, regardless of medication use.
OR1: adjusted for sex, age, BMI.
OR2: adjusted for sex, age, BMI, and antihypertensive medication.
P values for prevalence were from Chi-square test, p values for trend of ORs were from logistic regression, and p values for OR1 vs. OR2 were from 
Z-test.
Table 3: Muti-variable-adjusted means of blood pressure (mm Hg) among Gly482Ser and +2962A/G polymorphism in three subgroups
Genotypes Normotensives Hypertensive free from current 
antihypertensive medication
Current use of antihypertensive medication
N SBP(mm Hg) DBP(mm Hg) N SBP(mm Hg) DBP(mm Hg) N SBP(mm Hg) DBP(mm Hg)
G482S genotypes
G482G 250 119.7(0.6) 77.7(0.4) 86 150.7(1.4) 90.2(0.9) 155 151.2(1.9) 89.0(1.0)
G482S 428 120.1(0.5) 77.2(0.3) 155 149.6(1.1) 90.8(0.7) 209 152.6(1.6) 88.4(0.8)
S482S 169 121.3(0.7) 78.2(0.5) 61 148.6(1.8) 90.6(1.2) 86 144.8(2.5) 87.0(1.3)
p values 0.207 0.286 0.647 0.897 0.023 0.426
+2962A/G genotypes
+2962A/A 429 120.5(0.5) 77.6(0.3) 179 149.6(1.1) 90.9(0.7) 232 149.2(1.5) 87.4(0.8)
+2962A/G 336 120.1(0.5) 77.6(0.4) 127 150.2(1.3) 90.0(0.8) 178 151.0(1.8) 89.4(0.9)
+2962G/G 82 119.4(1.1) 77.2(0.7) 39 149.6(2.3) 91.0(1.5) 40 159.9(3.6) 89.4(1.9)
p values 0.580 0.899 0.930 0.667 0.020 0.181
Means and p values were adjusted for age, sex, and BMI. Values in () are standard errors.BMC Cardiovascular Disorders 2007, 7:33 http://www.biomedcentral.com/1471-2261/7/33
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develops light or moderate hypertension, which should
be mostly composed of those caused by environment fac-
tors because of the much higher prevalence of environ-
ment factors, and it is hardly to detect the effect of gene
among them. The dilution effect from environment fac-
tors plus the gene's "minor effect" makes it impossible or
very hardly to detect the effect of gene by using a lower cut
off to define hypertension. Otherwise, a very large sample
of more than tens or hundreds thousands participants is
needed to make up, as shown by our post hoc analysis of
power. As we knew, this is the first study found that PGC-
1α  gene variants had stronger associations with more
severe hypertension. These findings have very important
significance of generalization to other studies trying to
identifying genes for hypertension development.
In addition, blood pressure lowering treatment in China
is generally low (56.6% in this study), and it would be
more likely that treated patients have a more severe hyper-
tension and by that have a stronger link to genetic factors.
Our findings are also supported by the previous study
done by Oberkofler and colleagues[6]. They used day time
ambulatory blood pressure and defined hypertension as
SBP > 140mm Hg or DBP > 90mm Hg or use of antihyper-
tensive medication, and they found a significant associa-
tion between G482S and hypertension in men[6]. Because
the ambulatory blood pressure is lower than occasional
clinic blood pressure, their findings were actually in
accordance with ours.
Besides, we also found an additive synthetic effect of
G482S and +2962A/G genotypes. Although the mecha-
nisms to explain the effect remain unclear, some studies
did provide useful evidence. There is substantial evidence
for the existence of both monogenic and polygenic forms
of essential hypertension, although these are believed to
be modulated by both gene-environment and gene-gene
interactions[8]. It is well known that both monogenic and
polygenic forms of essential hypertension are often early-
onset and more severe [3]. As a coactivator of PPARγ,
PGC-1α  regulates PPARγ  gene expression which com-
bined with its ligands (thiazolidinediones) to suppress
angiotensin II (AII) type 1 receptor (AT1R) gene expres-
sion both at the mRNA and protein levels in vascular
smooth muscle cells(VSMCs)[4]. Activation of AT1R by
AII binding triggers a variety of signal transduction path-
ways including the mitogen-activated protein (MAP)
kinase pathway. AII exerts many biological effects such as
cell construction, proliferation, and migration of VSMCs
that contributes to the progression of hypertension and
atherosclerosis. PPARγ  phosphorylation by the MAP
kinase pathway may thus attenuate PPARγ-mediated
AT1R gene transcription suppression through the inhibi-
tion of PPARγ activity[18]. PGC-1α is also a coactivator of
other nuclear receptors, including thyroid hormone
receptor, the mineralocorticoid and estrogen receptors
(ER) α and β, which are also involved in blood pressure
control[6-8,19].
Our study also has some limitations. First, there were 32%
of none-responders in the study. The main reasons of not
attending includes busy at farming work, out to do private
small business, not having interest, and not like blood
being drawn. The possible bias can not be totally elimi-
nated though no reason was associated with hypertension
or biological tests. Second, a significant deviation from
the Hardy-Weinberg equilibrium (HW-E) was detected for
the +2962A/G polymorphism in our study. This contrasts
to the previous study by Oberkofler [6]. The findings that
G482S genotypes in the same gene were in accordance
with HW-E in both studies may not indicate that the devi-
ation from HW-E was directly due to genotyping error. We
retyped these polymorphisms independently using
sequencing method in eight participants and ensured no
genotyping error occurred. Finally, the possibility of type
Table 5: Haplotype combination analyses of G482S and +2962A/G for regular and severe hypertension in 1642 participants
Regular hypertension* Severe hypertension**
Haplotype combinations N Cases Prevalence,% OR1(95%CI) Cases Prevalence,% OR2(95%CI) p values for OR1 vs. OR2
S482S||+2962A/X 316 147 46.5% 1 38 12.0% 1.0
S482S||+2962G/G 0 0 0 0 0
G482X||+2962A/X 1165 569 48.8% 1.0(0.8–1.3) 192 16.5% 1.5(1.0–2.2) 0.131
G482X||+2962G/G 161 79 49.1% 1.0(0.7–1.5) 38 23.6% 2.6(1.5–4.4) 0.006
p values 0.753 0.989 0.005 0.002
* Regular hypertension: SBP  140 mm Hg or DBP  90mm Hg or current use of antihypertensive medications;
** Severe hypertension: SBP  160 mm Hg or DBP  100mm Hg, regardless of medication use.
OR1: adjusted for sex, age, BMI.
OR2: adjusted for sex, age, BMI, and antihypertensive medication.
X was used to represents all possible allele, e.g. +2962A/X stands for +2962A/A or +2962A/G.
P values for prevalence were from Chi-square test, p values for trend of ORs were from logistic regression, and p values for OR1 vs. OR2 were from 
Z-test.BMC Cardiovascular Disorders 2007, 7:33 http://www.biomedcentral.com/1471-2261/7/33
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1 error due to multiple tests is not eliminated but the sys-
tematic difference between regular and severe hyperten-
sion for both gene SNPs suggested that is not likely the
case.
Conclusion
In this study, we found that G482S and +2962A/G SNPs
of PGC-1α gene were only significantly associated with
severe hypertension defined by occasional clinic blood
pressure measurements. This finding suggested severe
hypertension rather than regular hypertension should be
used as the outcome in studies on association of genes
and blood pressure or hypertension, in order to have a
better power.
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